NeuroproteXeon is seeking international distribution partners to help us achieve our mission. We have completed the preclinical studies necessary for the filing of an IND (US) and RMS & CMS (EU). We own exclusive worldwide, royalty-free rights to Xenon + Xenex™ therapy.
Xenex™ is an inhaled gas that has shown promising potential as a neuroprotectant when administrated to a patient after a cardiac arrest, in combination with hypothermia/targeted temperature management [TH/TTM] therapy.
Phase II Superiority Study, published in JAMA in March 2016, showed statistically significantly less brain damage and directionally positive survival outcomes between a xenon plus TTM group versus a TTM alone group. Overall the study showed:
- Less brain damage
- Improved survival outcome
- Non toxicity
Contact: All partnering inquiries should be directed to email@example.com